A Study of OPC-262 in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical study is to evaluate the superiority of the efficacy of OPC-262
(2.5 mg, and 5 mg) to placebo in patients with type 2 diabetes after 24 week treatment in a
double-blind fashion and to evaluate the safety of OPC-262 to placebo.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.